Please assess the completion status of the following clinical trial:

Trial Title: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Male or female at least 18 years of age at time of screening who is determined to be eligible based on evaluation by a treating provider,~ 2. Documentation of genotype 1 (GT-1) infection, liver fibrosis staging by any AASLD/IDSA guideline approved measurement, and HIV status determination.~ 3. Chronic HCV genotype-1 infection prior to study enrollment. Chronic HCV-infection is defined as the following: positive for anti-HCV Ab or HCV RNA at least 6 months before screening, and positive for HCV RNA and anti-HCV Ab at the time of screening~ 4. Compensated liver disease, both with and without cirrhosis, as determined clinically by referring provider~ 5. If coinfected with HIV, stable HIV disease as determined by a treating provider~ 6. Subjects must be able to understand and adhere to the study visit schedule and all other protocol requirements, and must voluntarily sign and date an informed consent form, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.~EXCLUSION CRITERIA:~1. Women who are pregnant or breastfeeding~2. Screening laboratory analyses showing any of the following abnormal laboratory results:~   - Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min as estimated by the Modification of Diet in Renal Disease (MDRD) equation (utilized by LabCorp):~   eGFR = 175 times SerumCr(-1.154) age(-0.203 1.212 (if patient is black) 0.742 (if female)~3. Diagnosis of hepatocellular carcinoma as defined by pre-screening medical history~4. Any other conditions in the opinion of the investigator that would interfere with the compliance or endpoints of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: OTHER): Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).